miércoles, 7 de octubre de 2026
BuscarExplore
es.VIA.NEWS
Source trace. Via News points to the documents behind its reporting and shows what we drew from each — so you can check any claim. How we source
Source document· May 25, 2026

D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS?

View original at nasdaq.com
D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS? Shares of D-Wave QuantumQBTS struggled from January to mid-May, falling 32.3% amid the uncertainty surrounding its pace of commercialization, uneven revenue recognition and rising competition across quantum computing…
Opening lines of the source · short snapshot — read the full document at the original

Lo que extrajimos de esta fuente

The claims Via News extracted from this document. We point to the source; we don't replace it.

  • Q1 2026 bookings surged 1,994% year over year to a record $33.4 million, supported by a $20 million system sale to Florida Atlantic University and a $10 million two-year QCaaS agreement with a Fortune 100 company.

    60% confidence

  • D-Wave's sales pipeline more than doubled sequentially during Q1 2026.

    60% confidence

  • Remaining performance obligations climbed 563% year over year to $42.4 million.

    60% confidence

  • D-Wave faces execution risks tied to system-sale timing, backlog conversion, rising operating expenses from the Quantum Circuits acquisition, and intense competition with many commercial applications still emerging.

    60% confidence

  • D-Wave's roadmap targets approximately 175 physical qubits by 2028, 10 logical qubits by 2030, and 100 logical qubits by 2032.

    60% confidence

  • QBTS currently carries a Zacks Rank #3 (Hold).

    60% confidence

  • D-Wave's Advantage2 quantum system outperformed classical nodes in mining operations on the Postquant Labs blockchain testnet.

    60% confidence

  • D-Wave has $588 million in liquidity.

    60% confidence

  • A substantial portion of 2026 revenues will be recognized in the second half of the year as large system deals progress toward delivery and installation.

    60% confidence

  • D-Wave's collaboration with Shionogi produced a tenfold increase in desirable drug-like molecules versus classical machine learning approaches.

    60% confidence

  • D-Wave's forward 12-month P/S ratio of 179.30x is far above the sector average of 6.77x, above IonQ's 74.72x, but below Rigetti Computing's 244.38x.

    60% confidence

  • QBTS is projected to report 2026 earnings growth of 72.1% on revenue growth of 63.3% from the 2025 reported figure.

    60% confidence

Data points we hold from this source

D-Wave Quantum Inc. · market share179.30 price_to_sales_ratio
D-Wave Quantum Inc. · cash588 USD
D-Wave Quantum Inc. · backlog33.4 USD
Lo que sabemos · la inteligencia detrás de esta página
En vivo desde el sustrato
Lo que estamos viendo
Autumn 2026 Biopharma Catalyst Season: Late-Breaking Data, FDA Milestones and the Rise of AI-Designed Drugs
Late-September and early-October 2026 conferences (EASD, EADV, IGCS) brought a cluster of positive late-breaking trial readouts. These covered obesity and metabolic disease (Novo Nordisk's CagriSema), immunology (Lilly's EBGLYSS, tulisokibart) and oncology (Rina-S, Agenus BOT+BAL). Ahead lie hard regulatory catalysts, led by the 14 Nov 2026 FDA PDUFA date for ivonescimab. At the same time, Insilico-style AI-designed drugs such as rentosertib are showing anti-aging signals. That points to AI-driven drug discovery moving from concept toward clinical validation. Unrelated tech and regulatory items (Tesla Cybercab probe, xAI litigation, OpenAI agent incident) and the speculative QAIAx claims are peripheral to this story.
Nuestra lectura de los datos ›
Señales que seguimos
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patrones que observamos ›
Donde las fuentes discrepan
ING Group
Both facts record the same metric (shares_outstanding) for ING Group at the identical observation date (2025-12-31). FACT A states 2,902,437,688 shares; FACT B states 2,902 million shares (2,902,000,000). The difference is 437,688 shares (~0.015%). This is a genuine value conflict, though the discrepancy appears to result from FACT B rounding to the nearest million while FACT A provides the precise count.
Señalamos los conflictos abiertamente ›
Verificado recientemente
✓ Verificado con la fuente original
4,986
hechos rastreados a su fuente — y señalamos los que no se sostienen.
101 entidades seguidas4,986 hechos verificados con la fuente5,362 documentos fuente archivados
Consulta estos datos → isubstrate.com
D-Wave Stock Skyrockets 62% After Q1 Earnings: Time to Buy QBTS? — Source | Via News | es.VIA.NEWS